ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO163

Serum Magnesium Levels and Cognitive Function in Hemodialysis Patients: A Cross-Sectional Study

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Authors

  • Kato, Kazuhiko, Tokyo Jikeikai Ika Daigaku Igakubu Igakuka Jinzo Koketsuatsu Naikagaku, Minato-ku, Japan
  • Nakashima, Akio, Tokyo Jikeikai Ika Daigaku Igakubu Igakuka Jinzo Koketsuatsu Naikagaku, Minato-ku, Tokyo, Japan
  • Kobayashi, Arisa, Tokyo Jikeikai Ika Daigaku Igakubu Igakuka Jinzo Koketsuatsu Naikagaku, Minato-ku, Japan
  • Ohkido, Ichiro, Tokyo Jikeikai Ika Daigaku Igakubu Igakuka Jinzo Koketsuatsu Naikagaku, Minato-ku, Tokyo, Japan
  • Yokoo, Takashi, Tokyo Jikeikai Ika Daigaku Igakubu Igakuka Jinzo Koketsuatsu Naikagaku, Minato-ku, Tokyo, Japan
Background

Dementia is a global challenge for geriatric care and social welfare, including for aging dialysis patients. Previous studies have suggested a potential association between cognitive function and chronic kidney disease-mineral and bone disorder (CKD-MBD). The present study aims to evaluate this association among patients with hemodialysis.

Methods

We conducted a cross-sectional study of patients with hemodialysis to examine the association between cognitive functions, as assessed by the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), and serum magnesium, intact parathyroid hormone (PTH), 25-hydroxyvitamin D(OHD), Fibroblast Growth Factor(FGF)-23, and soluble α-Klotho.

Results

This study involved 390 patients whose median age was 74 (70-80) years and who had been receiving hemodialysis for an average of 87 (36-168) months. The mean serum magnesium level was 2.4 ±0.3 mg/dL, and the median intact PTH and 25-OHD levels were 157 (94-238) pg/mL and 14.1 (10-19.6) ng/mL. The median intact FGF-23 and soluble α-Klotho levels were 1921 (602-4840) pg/mL and 381 (300-517) pg/mL. The median MoCA and MMSE scores were 25 (22-26) and 28 (26-29). The MoCA and MMSE score were significantly higher (cognitive function is preserved) in patients with higher magnesium levels than lower magnesium after adjusted multivariate analysis (β coefficient [95% confidence interval], 0.91 [0.03, 1.78]; P=0.043 for MoCA, and 0.82 [0.13, 1.5]; P=0.019 for MMSE). There were no significant associations between cognitive functions and serum intact PTH, 25OHD, FGF-23, and soluble α-Klotho levels.

Conclusion

Higher serum magnesium levels were associated with preserved cognitive function in hemodialysis patients, and avoiding hypomagnesemia may be recommended to protect cognitive function. On the other hand, no significant associations were observed between cognitive functions and serum intact PTH, 25OHD, FGF-23, and soluble α-Klotho levels.

Funding

  • Private Foundation Support